Biocon announces full integration of its biosimilars unit, Biocon Biologics, in a deal valuing it at $5.5 billion. The move aims to create a unified powerhouse in diabetes, oncology, and immunology markets. Read more.
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
Biocon stock jumps over 4% as company reviews Biologics IPO and merger options to unlock shareholder value and reduce debt. Latest market updates and analysis.
Biocon's generics business surges 24% driven by weight-loss drugs liraglutide & semaglutide. CEO Siddharth Mittal reveals strategy to capture share of the booming $95 billion GLP-1 market.
Federal health officials are accelerating efforts to bring cheaper biotech drugs to market, potentially transforming treatment access and creating new opportunities for Indian pharmaceutical companies.